FDA Limits COVID-19 Boosters to Seniors, Other High-Risk Groups
By I. Edwards HealthDay Reporter
WEDNESDAY May 21, 2025 — The U.S. Food and Drug Administration (FDA) has decided that only seniors and people at high risk should get the latest COVID-19 booster shots this fall.
The new framework, announced Tuesday, says adults 65 and older, and people with certain health conditions, can still get updated COVID-19 vaccines, The Associated Press reported.
These changes are meant to limit the use of the shots while experts collect more data on how well they work for healthy people.
Dr. Vinay Prasad, the FDA’s top vaccine official, said more than 100 million Americans would still qualify for the boosters.
“For many Americans we simply do not know the answer as to whether or not they should be getting the seventh or eighth or ninth or tenth COVID-19 booster,” Prasad said.
The FDA laid out its new framework in the New England Journal of Medicine and during a live webcast. This is a shift from the agency’s previous approach, which made COVID-19 boosters available to nearly all adults, just like the flu shot.
Going forward, vaccine makers like Pfizer and Moderna must run large, long-term studies in healthy people before those shots can be approved for broader use.
“Is the pharmacist going to determine if you’re in a high-risk group?” said Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia.
“The only thing that can come of this will make vaccines less insurable and less available," he said in a report from AP.
The American Academy of Pediatrics (AAP) also raised concerns.
“If the vaccine were no longer available or covered by insurance, it will take the choice away from families who wish to protect their children from COVID-19, especially among families already facing barriers to care,” said Dr. Sean O’Leary, chair of the AAP Committee on Infectious Diseases.
In 2023, 231 children died from COVID-related causes, which is similar to a typical flu season, according to AP.
The move is part of a broader effort by the Trump administration to review how COVID vaccines are handled. Last week, the FDA gave full approval to Novavax’s COVID shot but also limited it to certain groups.
FDA Commissioner Dr. Marty Makary, co-author of the new guidance, said the U.S. needs to move away from a "one-size-fits-all" approach to vaccines, AP reported.
The FDA plans a new trial to see how well boosters work in healthy adults.
This new guidance comes just ahead of a June meeting in which advisors to the U.S. Centers for Disease Control and Prevention are to discuss who should get COVID-19 shots going forward.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-22 00:00
Read more

- Transcranial Pulse Current Stimulation Beneficial in Autism
- Ready-Made Immune Therapy Effective Against Leukemia
- Europe Launches $565 Million Campaign to Attract U.S. Scientists
- FDA Approves Zevaskyn for Rare, Genetic Skin Disorder
- Icotrokinra Results Show Significant Skin Clearance in Patients with Difficult-to-Treat Scalp and Genital Psoriasis
- Boehringer Ingelheim Starts Phase II Study of its Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions